首页 | 本学科首页   官方微博 | 高级检索  
检索        

大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病的临床观察
引用本文:罗华山.大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病的临床观察[J].中国当代医药,2012(5):76-77.
作者姓名:罗华山
作者单位:广东省梅州市人民医院
摘    要:目的观察大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病的疗效与安全性。方法观察本院应用大剂量甲氨蝶呤治疗的33例不同程度急性淋巴细胞白血病患儿的治疗效果,监测用药后不同时间点的血药浓度以及用药后的不良反应发生率。结果标危组44h与68h时的血药浓度分别为(1.12±0.37)μmol/L与(0.41±0.22)μmol/L,中高危组分别为(0.82±0.32)μmol/L与(0.23±0.16)μmol/L,两组68h时的血药浓度均显著低于44h时的血药浓度,P〈0.01;两组不良反应与排泄延迟发生率无明显差异,P〉0.05。结论应用大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病后,通过血药浓度监测在恰当时间内采取四氢叶酸钙解救可有效提高治疗效果,减轻不良反应程度。

关 键 词:急性淋巴细胞白血病  甲氨蝶呤  疗效观察  儿童

The clinical observation of the treatment of high-dose methotrexate for children with acute lymphoblastic leukemia
Authors:LUO Huashan
Institution:LUO Huashan The People’s Hospital of Meizhou City in Guangdong Province, Meizhou 514031, China
Abstract:Objective To observe the effect and safety of the treatment of high-dose methotrexate for children with acute lymphoblastic leukemia. Methods Observed the clinical effect of high-dose methotrexate in the treatment of 33 cases of children patients with varying degrees of acute lymphoblastic, monitored plasma concentration of different time points after medication and the incidence of adverse reactions after treatment. Results The plasma concentration of standard risk group in 44 h and 68 h were (1.12±0.37) μmol/L and (0.41±0.22) μmol/L, high-risk group were (0.82±0.32) μmol/L and (0.23±0.16) μmol/L, the plasma concentration of two groups in 68 h were significantly lower than the plasma concentration in 44 h, P < 0.01; Adverse reactions and delayed excretion of two groups were no significant differences, P > 0.05. Conclusion After the application of the treatment of high-dose methotrexate for children with acute lymphoblastic leukemia, through the blood concentration to take leucovorin rescue treatment at the right time can effectively improve the treatment effect, reduce the degree of adverse reactions.
Keywords:Acute lymphoblastic leukemia  Methotrexate  Efficacy observation  Children
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号